| Literature DB >> 33345021 |
Julien Lapointe1, Pénélope Paradis-Deschênes1, Xavier Woorons2, Fréderic Lemaître3, François Billaut1.
Abstract
This study investigated the impact of repeated-sprint (RS) training with voluntary hypoventilation at low lung volume (VHL) on RS ability (RSA) and on performance in a 30-15 intermittent fitness test (30-15IFT). Over 4 weeks, 17 basketball players included eight sessions of straight-line running RS and RS with changes of direction into their usual training, performed either with normal breathing (CTL, n = 8) or with VHL (n = 9). Before and after the training, athletes completed a RSA test (12 × 30-m, 25-s rest) and a 30-15IFT. During the RSA test, the fastest sprint (RSAbest), time-based percentage decrement score (RSASdec), total electromyographic intensity (RMS), and spectrum frequency (MPF) of the biceps femoris and gastrocnemius muscles, and biceps femoris NIRS-derived oxygenation were assessed for every sprint. A capillary blood sample was also taken after the last sprint to analyse metabolic and ionic markers. Cohen's effect sizes (ES) were used to compare group differences. Compared with CTL, VHL did not clearly modify RSAbest, but likely lowered RSASdec (VHL: -24.5% vs. CTL: -5.9%, group difference: -19.8%, ES -0.44). VHL also lowered the maximal deoxygenation induced by sprints ([HHb]max; group difference: -2.9%, ES -0.72) and enhanced the reoxygenation during recovery periods ([HHb]min; group difference: -3.6%, ES -1.00). VHL increased RMS (group difference: 18.2%, ES 1.28) and maintained MPF toward higher frequencies (group difference: 9.8 ± 5.0%, ES 1.40). These changes were concomitant with a lower potassium (K+) concentration (group difference: -17.5%, ES -0.67), and the lowering in [K+] was largely correlated with RSASdec post-training in VHL only (r = 0.66, p < 0.05). However, VHL did not clearly alter PO2, hemoglobin, lactate and bicarbonate concentration and base excess. There was no difference between group velocity gains for the 30-15IFT (CTL: 6.9% vs. VHL: 7.5%, ES 0.07). These results indicate that RS training combined with VHL may improve RSA, which could be relevant to basketball player success. This gain may be attributed to greater muscle reoxygenation, enhanced muscle recruitment strategies, and improved K+ regulation to attenuate the development of muscle fatigue, especially in type-II muscle fibers.Entities:
Keywords: breath-hold; hypoventilation; hypoxia; muscle oxygenation; muscle recruitment; potassium; repeated-sprint ability
Year: 2020 PMID: 33345021 PMCID: PMC7739750 DOI: 10.3389/fspor.2020.00029
Source DB: PubMed Journal: Front Sports Act Living ISSN: 2624-9367
Figure 1Layout of repeated sprint exercise with changes of direction (COD) on a basketball court.
Mean changes in performance and perceptual exercise responses in the repeated-sprint ability (RSA) and the 30-15IFT tests after repeated-sprint training performed with voluntary hypoventilation at low lung volume (VHL) or normal breathing (CTL).
| RSAbest | VHL | 4.80 ± 0.35 | 4.86 ± 0.36 | 0.15 ± 0.17 | 31/61/0 |
| RSAmean | VHL | 5.16 ± 0.47 | 5.03 ± 0.41 | −0.27 ± 0.19 | 0/26/74 |
| RSASdec | VHL | 7.25 ± 3.18 | 5.49 ± 2.70 | −0.47 ± 0.40 | 1/12/88 |
| RPE RSA | VHL | 7.5 ± 1.15 | 7.08 ± 1.22 | −0.32 ± 0.30 | 1/23/77 |
| VIFT | VHL | 18.78 ± 1.68 | 20.18 ± 1.39 | 0.81 ± 0.32 | 100/0/0 |
| RPE 30–15 | VHL | 7.58 ± 0.68 | 7.94 ± 0.76 | 0.43 ± 0.59 | 76/20/4 |
Data are presented as means ± SD. Cohen's effect size ± 90% confidence limits. Clear changes within and between groups are indicated in bold. RSA.
Figure 2Completion time for every sprint of the RSA test performed with normal breathing (CTL) and voluntary hypoventilation at low volume (VHL) before and after 4 weeks of repeated-sprint training. Data are presented as means ± SE. *Small effect between groups.
Figure 3Peak (A) and nadir (B) values of normalized deoxyhemoglobin concentration ([HHb]) over 11 sprint/recovery cycles with normal breathing (CTL) and voluntary hypoventilation at low lung volume (VHL) before and after 4 weeks of training. Data are presented as means ± SD, expressed as a percent of the first sprint/recovery cycle. **Moderate effect between groups; †Large effect between groups.
Figure 4Percentage difference and qualitative interference in the change in NIRS variables from Pre- to Post- in VHL compared to CTL.
Figure 5Changes in normalized EMG amplitude (RMS) (A) and median power frequency (MPF) (B) of the biceps femoris and gastrocnemius muscles during 12 sprints with normal breathing (CTL) and voluntary hypoventilation at low lung volume (VHL) before and after 4 weeks of training. Data are presented as means ± SD, expressed as a percent of sprint 1. Large effect between groups. The RMS values decreased from 0.45 ± 0.15 mV to 0.35 ± 0.13 mV in Pre- and from 0.43 ± 0.17 mV to 0.31 ± 0.11 mV in Post- in the CTL group. In VHL, RMS decreased from 0.41 ± 0.11 mV to 0.31 ± 0.14 mV in Pre- and from 0.41 ± 0.11 mV to 0.32 ± 0.14 mV in Post-. Average MPF values decreased from 105.5 ± 25.2 Hz to 99.2 ± 23.8 Hz in Pre- and from 104.6 ± 25.3 Hz to 91.4 ± 25.4 Hz in Post- in CTL group. In VHL, MPF decreased from 112.3 ± 17.0 Hz to 108.4 ± 16.3 Hz in Pre- and from 106.6 ± 17.4 Hz to 100.1 ± 18.1 Hz in Post-.
Mean changes in blood parameters following the RSA test after repeated-sprint training performed with voluntary hypoventilation at low lung volume (VHL) or normal breathing (CTL).
| pH | 7.22 ± 0.04 | 7.25 ± 0.06 | 7.22 ± 0.08 | 7.23 ± 0.09 | −0.4 ± 0.5 | – | 4/23/73 |
| PCO2 (mmol·L–1) | 31.95 ± 3.10 | 30.88 ± 3.85 | 31.36 ± 5.11 | 32.46 ± 2.60 | 8.5 ± 11.2 | 82/14/5 | |
| PO2 (mmol·L–1) | 88.53 ± 2.33 | 88.85 ± 5.04 | 92.64 ± 11.60 | 89.81 ± 8.34 | −3.0 ± 7.7 | −0.33 ± 0.8 | 13/26/61 |
| [Na+] (mmol·L−1) | 144.00 ± 1.67 | 144.67 ± 2.25 | 144.75 ± 4.68 | 144.00 ± 1.77 | −0.9 ± 2.5 | −0.44 ± 1.15 | 17/19/65 |
| [K+] (mmol·L−1) | 5.02 ± 0.3 | 5.67 ± 1.33 | 6.73 ± 2.64 | 5.93 ± 1.41 | −17.5 ± 31.2 | 5/13/80 | |
| [Ca++] (mmol·L−1) | 1.25 ± 0.02 | 1.25 ± 0.05 | 1.29 ± 0.08 | 1.29 ± 0.06 | −0.7 ± 4.4 | −0.13 ± 0.86 | 25/30/44 |
| [Cl−] (mmol·L−1) | 112.83 ± 2.56 | 113.00 ± 3.58 | 114.00 ± 6.57 | 113.75 ± 4.17 | −0.3 ± 5.3 | −0.06 ± 1.25 | 36/22/42 |
| [Glu] (mmol·L−1) | 8.53 ± 1.27 | 8.35 ± 1.22 | 7.49 ± 0.89 | 7.33 ± 0.91 | −0.2 ± 4.7 | −0.01 ± 0.30 | 12/74/14 |
| [Lac−] (mmol·L−1) | 13.49 ± 1.51 | 12.12 ± 1.53 | 14.03 ± 2.38 | 12.98 ± 2.97 | 2.1 ± 12.4 | 0.11 ± 0.63 | 40/40/19 |
| Hct (%) | 45.67 ± 2.94 | 47.33 ± 3.93 | 46.13 ± 5.94 | 46.88 ± 4.70 | −1.5 ± 4.4 | −0.15 ± 0.41 | 8/51/41 |
| [ | 13.05 ± 1.99 | 13.65 ± 1.78 | 12.98 ± 2.92 | 13.79 ± 2.72 | 1.7 ± 13.7 | 0.09 ± 0.69 | 39/38/23 |
| [cTCO2] (mmol·L−1) | 14.02 ± 2.04 | 14.58 ± 1.82 | 13.93 ± 2.99 | 14.78 ± 2.72 | 2.2 ± 13.8 | 0.12 ± 0.73 | 42/36/21 |
| BE(ecf) (mmol·L−1) | −14.70 ± 2.54 | −13.52 ± 2.48 | −14.74 ± 3.86 | −13.79 ± 4.07 | −0.2 ± 1.9 | −0.07 ± 0.55 | 20/47/33 |
| BE(b) (mmol·L−1) | −13.47 ± 2.45 | −12.10 ± 2.51 | −13.46 ± 3.75 | −12.61 ± 4.07 | −0.5 ± 1.8 | −0.15 ± 0.53 | 13/43/43 |
| SpO2 (%) | 94.85 ± 0.45 | 95.35 ± 0.89 | 95.28 ± 1.44 | 95.14 ± 0.75 | −0.7 ± 1.1 | −0.61 ± 1.04 | 9/15/76 |
| cHgb (g·dL−1) | 15.48 ± 0.96 | 16.05 ± 1.30 | 15.65 ± 2.03 | 15.83 ± 1.59 | −2.0 ± 4.5 | −0.20 ± 0.43 | 6/44/49 |
Data are presented as means ± SD. Cohen's effect size ± 90% confidence limits. Clear changes between groups are indicated in bold.